4.2 Article

Hypertension in FMR1 premutation males with and without fragile X-associated tremor/ataxia syndrome (FXTAS)

期刊

AMERICAN JOURNAL OF MEDICAL GENETICS PART A
卷 158A, 期 6, 页码 1304-1309

出版社

WILEY
DOI: 10.1002/ajmg.a.35323

关键词

hypertension; FMR1 premutation; fragile X-associated tremor; ataxia syndrome; autonomic disease

资金

  1. National Institute of Health [HD036071, HD02274]
  2. Neurotherapeutic Research Institute (NTRI) [DE019583, DA024854]
  3. National Institute on Aging [AG032119, AG032115, MH078041]
  4. National Center for Research Resources [UL1 RR024146]
  5. Health and Human Services Administration of Developmental Disabilities [90DD05969]
  6. Seaside Therapeutics
  7. Roche Pharmaceuticals
  8. Novartis
  9. Forest
  10. Curemark

向作者/读者索取更多资源

Fragile X-associated tremor ataxia syndrome (FXTAS) is a late onset neurodegenerative disease that affects carriers of the fragile X premutation. This study seeks to assess hypertension risk and susceptibility in male premutation carriers with FXTAS. Although many symptoms and diagnostic criteria have been identified, hypertension risk has not been examined in this population. Data from 92 premutation carriers without FXTAS, 100 premutation carriers with FXTAS, and 186 controls was collected via patient medical interview. Age-adjusted logistic regression analysis was used to examine the relative odds of hypertension. We observed a significantly elevated odds ratio (OR) of hypertension relative to controls for premutation carriers with FXTAS (OR=3.22, 95% CI: 1.726.04; P=0.0003) among participants over 40-year old. The age-adjusted estimated odds of hypertension in premutation carriers without FXTAS in the over 40-year-old age group was higher compared to controls (OR=1.61, 95% CI: 0.823.16), but was not statistically significant (P=0.164). Chronic hypertension contributes to cardiovascular complications, dementia, and reased risk of stroke. Our results indicate that the risk of hypertension is significantly elevated in male premutation carriers with FXTAS compared with carriers without FXTAS and controls. Thus, evaluation of hypertension in patients diagnosed with FXTAS should be a routine part of the treatment monitoring and intervention for this disease. (c) 2012 Wiley Periodicals, .

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据